Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07757178

Lived Experience Narratives in Dementia

Lived Experience Narratives in Dementia — Recruiting • Non-phase study • Neurology • NCT07757178.

📅 11 Aug 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07757178
Sponsor
University of Nottingham
Start
2025-11-17
ClinicaliQ Trial Snapshot
  • Lived Experience Narratives in Dementia — Recruiting • Non-phase study • Neurology • NCT07757178.
  • What is being tested: The LEND research programme is investigating how narrative-based interventions can benefit people living with dementia across multiple work packages, with WP1 examining how dementia patients use and respond to narratives as a foundation for developing therapeutic theory.
  • Patient eligibility overview: The trial involves people living with dementia as primary participants, with the research design spanning multiple work packages (WP1-5) to systematically explore narratives' role and application in this population, though specific inclusion/exclusion criteria would be detailed in individual work….
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them. Findings will support the development of LEND theory. WP 2-3 focus on developing the digital Online LEND Intervention, assessing its usability and acceptability, and conducting a feasibility study within NHS memory assessment and community services. Activities across the first three WPs include interviews, focus groups, user-testing sessions, engagement evaluation interviews, and a two-arm randomised feasibility trial using a range of outcome…

Eligibility Snapshot
  • General Inclusion Criteria (apply across WP1-WP3) * Adults aged 18+. * Able to give informed consent and participate meaningfully in the required tasks. * Adequate communication ability in the required study language General

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Smart beds and motion sensors – is this the future of dementia care?
Neurology · BBC Health · 20 Sep 2026
Key takeaways for clinical practice: Smart home technology including motion sensors, bed monitors, and wearable devices (socks) can enable remote monitoring of…
View brief →
Clinical Brief
‘My son can now enjoy life’: Children with severe form of epilepsy helped by new drug
Neurology · BBC Health · 04 Mar 2026
Fenfluramine has demonstrated clinical benefit in children with Dravet syndrome, a severe and treatment-resistant form of early-onset epilepsy, with families reporting significant…
View brief →
Clinical Brief
Nobel Prize awarded for revealing inner workings of the brain
Neurology · BBC Health · 05 Oct 2026
Karl Deisseroth, Peter Hegemann, and Georg Nagel have been awarded the Nobel Prize for developing optogenetics, a technique enabling precise control of…
View brief →
Guideline
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment
Neurology · 01 Oct 2026
AI-assisted EEG interpretation software can support clinicians in identifying abnormalities suggestive of epilepsy, but should complement rather than replace expert clinical review—use…
View guideline →
Clinical Brief
Diabetes and ADHD drugs to be tested on Alzheimer’s patients in new study
Neurology · BBC Health · 21 Oct 2026
Diabetes and ADHD medications are being simultaneously tested as potential Alzheimer's treatments, potentially accelerating drug development timelines for this common dementia type…
View brief →
Guideline
Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years
Neurology · 16 Sep 2026
Mirdametinib is indicated for symptomatic and inoperable plexiform neurofibromas in children aged 2-17 years with neurofibromatosis type 1 (NF1); confirm diagnosis and…
View guideline →